March 2011 Central Nervous System

Attention-Deficit/Hyperactivity Disorder and Treatment

March 14, 2011

Features

Attention-deficit/hyperactivity disorder is a complex developmental condition that often negatively influences a patient's academic, professional, or social life. Treatment is usually multifaceted and complicated, and requires careful monitoring.

Shionogi Pharma's Kapvay

March 14, 2011

Rx Product News Profile

The FDA approved Kapvay (clonidine hydrochloride extended -release) as a monotherapy and adjunctive therapy for the treatment of attention- deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.